Open company graph database — free web & API
Login

Tirots Pharma

ティロッツ・ファーマ
Ticker
—
Listed market
—
Country
Switzerland
Employees (non-consolidated)
—
Related companies
0
§01

Basic information

BASIC
Head office
Switzerland
Chief executive
Employees (non-consolidated)
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

2
Manufacture and sale of inflammatory bowel disease treatmentsManufacture and sale of pharmaceuticals
§04

Related companies

0 COMPANIES

—

§05

Network

NETWORK
Drag to move · click to open
§06

History

60 EVENTS

Establishment of Zeria Pharmaceutical Research Institute Ltd. (Chuo-ku, Tokyo, capital of 3 million yen)Sources

Release of the pharmaceutical "Chondroitin"Sources

Release of joint pain and lower back pain treatment "Chondroitin ZS Tablets"Sources

Release of "Hepalyse Tablets"Sources

Changed trade name to Zeria Shinyaku Kogyo Co., Ltd.Sources

New construction of Saitama Factory in Kounan-cho, Osato-gun, Saitama Prefecture (now Kumagaya City)Sources

Release of "New Hepalyse", a tonic and liver hydrolysate formulationSources

New construction of Central Research Institute in Kounan-cho, Osato-gun, Saitama Prefecture (now Kumagaya City)Sources

Release of absorbable topical hemostatic agent "Abiten", introduced and developed from Alcon Inc. in the United StatesSources

Release of plant-based laxative "WithOne"Sources

New construction of Tsukuba Factory in Katsura, Ushiku City, Ibaraki PrefectureSources

Introduction from Eli Lilly & Co. in the United States, jointly developed with Eli Lilly Japan Co., Ltd., of the gastric ulcer treatment "Asinon Capsules 150"Sources

Release of "Answer 20 Injection", a drug to suppress leukopenia caused by radiation therapySources

Joint development with Chugai Pharmaceutical Co., Ltd., of the non-steroidal analgesic and anti-inflammatory drug "Peon Tablets 80"Sources

Joint development with Nissan Chemical Industries, Ltd., of the antihypertensive drug "Randel Tablets 10 & 20"Sources

Release of the zinc-containing gastric ulcer treatment "Promac Granules 15%"Sources

Release of "New Hepalyse Plus", a tonic and liver hydrolysate formulationSources

Listed on the Tokyo Stock Exchange Second Section on December 22. Completely renewed symbol mark and company logoSources

Commissioning logistics operations to Itochu Corporation and its affiliates Super Rex to activate a new logistics systemSources

Listed on the First Section of the Tokyo Stock Exchange on March 1Sources

Contract with Swiss company Tilott's Pharma for the development, manufacturing, and sale of the inflammatory bowel disease treatment drug "Asacol" in JapanSources

Launch of "New Hepalyse Drink," a tonic and liver hydrolysate-containing beverageSources

Chondroitin group sales surpass 5 billion yenSources

Launch of zinc-containing gastric ulcer treatment "Promac D Tablets 75"Sources

Expansion of Tsukuba Factory Building No. 2Sources

Launch of "Bisclear Tablets," a colon cleansing agent before colonoscopySources

Launch of "Asinon Tablets 75mg and 150mg" for gastritis and ulcer treatmentSources

Start of TV commercials for "Chondroitin ZS Tablets"Sources

Acquisition of all shares of Ionaine International and making it a subsidiarySources

Acquisition of all shares of Swiss company Tilott's Pharma and making it a subsidiarySources

Launch of "Asacol Tablets 400mg" for ulcerative colitis treatmentSources

Start of TV commercials for "New Hepalyse Drink"Sources

Acquisition of shares of Danish ZPD (formerly Biofock Esbia) and making it a subsidiarySources

Launch of "Hepalyse W," a beverage for convenience storesSources

Launch of "New Wizone," a plant-based laxativeSources

Start of TV commercials for "New Wizone"Sources

Launch of "Hosribon," a low-phosphorus treatment drugSources

Launch of "Acofide Tablets 100mg" for functional dyspepsia treatmentSources

Launch of convenience store-oriented soft drink "Heparlyze W Hyper"Sources

Launch of premenstrual syndrome treatment drug "PreFemin"Sources

Launch of convenience store-oriented carbonated beverage "Heparlyze W Sparkling"Sources

Tylott's Pharma acquired rights for "Entocort" excluding the US from AstraZeneca for worldwide rightsSources

Acquired 49% of shares of Pharmaceutical Joint Stock Company of February 3rd (now a consolidated subsidiary) and made it a subsidiarySources

Launch of nourishing tonic and liver hydrolysate containing "Heparlyze Plus II"Sources

Launch of convenience store-oriented soft drink "Heparlyze W Premium"Sources

Heparlyze group sales exceeded 10 billion yenSources

Additional acquisition of shares of Pharmaceutical Joint Stock Company of February 3rd (now a consolidated subsidiary), increasing ownership to 77.89%Sources

Launch of nourishing mini drink "Heparlyze King Plus" and "Heparlyze King EX"Sources

Launch of Crohn's disease treatment drug "Zentacort Capsule 3mg"Sources

Launch of convenience store-oriented soft drink "Heparlyze W Premium Extreme"Sources

Acquired all shares of Kensou Pharmaceutical (formerly Nihon Suisei Pharmaceutical) and made it a subsidiarySources

Launch of iron deficiency anemia treatment drug "Fainject Intravenous Injection 500mg"Sources

Succession of manufacturing and sales rights for "Deficliar Tablets" for Clostridioides difficile infection from Astellas Pharma Europe Ltd. to Tillotts Pharma AG (now a consolidated subsidiary) for Europe, Middle East, Africa, and the Commonwealth of Independent StatesSources

Launch of drug "Belfemin" to improve mild venous reflux disorder and leg swellingSources

Launch of drug "Corpermin" for irritable bowel syndrome (IBS) improvementSources

Transition from the First Section to the Prime Market of the Tokyo Stock Exchange due to review of market segmentsSources

Succession of manufacturing and sales approval for "Dafclear Tablets 200mg" for infectious enteritis caused by Clostridioides difficile from Astellas Pharma to the companySources

Launch of convenience store-oriented soft drink "Heparlyze W Shine"Sources

Launch of the hyperkalemia treatment drug "Viltasa Suspension Pack 8.4g"Sources

Absorption merger of Kensō PharmaceuticalSources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑